Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients?

Balkan, Ayhan; Namıduru, Mustafa; Balkan, Yasemin; Mete, Ayşe Özlem; Karaoğlan, İlkay; Boşnak, Vuslat

doi:10.4103/1319-3767.182454

Cited by 10 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have investigated the correlation of serum HBsAg and HBV DNA with liver pathological grades and stages in patients with chronic HBV infection [31][32][33][34][35][36]. e results of this study were basically consistent with those studies.…”

Section: Discussionsupporting

confidence: 89%

Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection

Zhang

Shi

et al. 2019

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Background. Changes of hepatitis B core antigen antibody (anti-HBc) in liver pathological involvement in patients with chronic hepatitis B virus (HBV) infection have not been investigated in detail. This study aimed to explore evolving patterns of anti-HBc following liver pathological states and to investigate validities of anti-HBc for predicting liver pathological states. Methods. 254 HBeAg-positive and 237 HBeAg-negative patients with chronic HBV infection were enrolled. Liver pathological diagnoses referred to Scheuer standard, and anti-HBc was measured using chemiluminescence microparticle immunoassay. Results. Anti-HBc was significantly positively correlated with pathological grades and stages in both HBeAg-positive (rs = 0.312, P<0.0001, and rs = 0.268, P<0.0001) and HBeAg-negative (rs = 0.270, P<0.0001, and rs = 0.147, P=0.0237) patients. The medians of anti-HBc in pathological grades of G1, G2, and G3 and stages of S1, S2, S3, and S4 in HBeAg-positive patients were all significantly lower than those in HBeAg-negative patients (all P<0.005). The areas under receiver-operating characteristic curves (95% confidence interval) of anti-HBc for predicting pathological grades ≥G2 and ≥G3, and stages ≥S2 and =S4 in HBeAg-positive patients were 0.683 (0.622–0.740) and 0.662 (0.601–0.720), and 0.627 (0.564–0.687) and 0.683 (0.622–0.740), respectively, and in HBeAg-negative patients were 0.681 (0.618–0.740) and 0.702 (0.639–0.760), and 0.569 (0.503–0.633) and 0.630 (0.565–0.691), respectively. Conclusion. Following hepatic aggravation of necroinflammation and progression of fibrosis, anti-HBc increases gradually in HBeAg-positive patients and continues to increase gradually in HBeAg-negative patients, which is a useful but unsatisfactory marker for monitoring pathological states.

show abstract

Section: Discussionsupporting

confidence: 89%

Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection

Zhang

Shi

et al. 2019

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

show abstract

“…In HBeAg-positive CHB patients, a moderate positive correlation was detected between serum qHBsAg level and HBV DNA, but no correlation was found between the serum qHB-sAg level and ALT, HAI severity or the fibrosis stage. In HBeAg-negative hepatitis B infection and HBeAg-negative CHB group no correlation was reported between serum qHBsAg level, ALT, HAI, and fibrosis [15].…”

Section: Discussionmentioning

confidence: 85%

Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients

Tatar

Acar

Adar

et al. 2020

ceh

View full text Add to dashboard Cite

Aim of the study: The quantitative hepatitis B surface antigen (qHBsAg) level indicates the amount of transcriptional activity of covalently closed circular DNA (cccDNA) and integrated DNA in hepatocytes which plays a role in development of chronic hepatitis B (CHB) and may help decide whether the treatment is necessary or not. The aim of this study is to evaluate the association between serum qHBsAg levels and viral replication and stage of liver fibrosis in treatment-naive CHB patients and to determine the role of qHBsAg levels in predicting when liver biopsy is necessary. Material and methods: 967 patients were included in the study. Because of refusal of liver biopsy the study was conducted on 123 patients. The association between qHBsAg levels with HBV DNA, a-fetoprotein, fibrosis stage and histology activity index was evaluated. Results: Of the patients, mean age was 48 ±11.2 years and 56.1% were male. We found that patients with HBV DNA ≥ 2000 IU/ml had a higher qHBsAg titer in comparison with HBV DNA < 2000 IU/ml. However, there was no relationship between qHBsAg titer and liver necroinflammation or fibrosis stage. Conclusions: Monitoring of qHBsAg together with HBV DNA may be helpful in CHB management. However, qHBsAg level does not provide knowledge about the timing of biopsy or the decision of CHB treatment.

show abstract

“…In our study we found that in the group of IC there is intermediate strong positive correlation between HBsQ and HBV DNA, Spearman Rank R=0.45 ( p<0.05), while in the HBeAg-negative group there is intermediate weak positive statically insignificant correlation Spearman Rank R=0.31 and p>0.05. In the study of Balkan [17] 204 patients with chronic hepatitis B were investigated, IC and patients with chronic active hepatitis B, and the correlation between HBsQ and HBV DNA, ALT level, liver fibrosis and HAI index was investigated. No correlation was found in the inactive carrier group, but intermediate positive correlation was found in the patients with chronic HBeAg positive hepatitis B [17].…”

Section: Discussionmentioning

confidence: 99%

“…In the study of Balkan [17] 204 patients with chronic hepatitis B were investigated, IC and patients with chronic active hepatitis B, and the correlation between HBsQ and HBV DNA, ALT level, liver fibrosis and HAI index was investigated. No correlation was found in the inactive carrier group, but intermediate positive correlation was found in the patients with chronic HBeAg positive hepatitis B [17]. Unlike the Balkan's study, our study did not investigate the correlation between quantitative HBsAg and serum HBV DNA in patients with chronic HBeAg positive hepatitis B, but we found intermediate positive correlation between the investigated parameters in patients with HBeAg-negative chronic hepatitis B, and not in the inactive carrier group.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Quantitative HBs Antigen in the Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B

Dimzova

Kondova-Topuzovska

Milenkovic

et al. 2018

Prilozi

View full text Add to dashboard Cite

The assessment of liver fibrosis in patients with chronic hepatitis B (CHB) is of great importance in evaluating the phases of chronic hepatitis B viral infection, prompt administration of antiviral therapy, prevention of disease progression and late complications of CHB infection. Aim: to investigate the clinical significance of quantitative HBs antigen as a predictor for liver fibrosis in patients with HBe antigen negative chronic hepatitis B and inactive carriers. Material and Methods: the study included 44 treatment naïve patients with chronic hepatitis B, divided into two groups, HBeAg negative chronic HBV infection or inactive carriers (IC) and HBeAg negative chronic hepatitis B patients. All patients underwent laboratory, serologic testing, ultrasound and transient elastography (TE). In both patient groups, quantitative HBs antigen (HBsQ), alanine aminotransferase (ALT), hepatitis B virus deoxyribonucleic acid (HBV DNA) and liver fibrosis were analyzed. Results: The value of HBsQ is significantly higher in patients with HBeAg negative CHB 2477.02±4535.44 IU/ml than in the IC group 8791±11891 IU/ml; Z=3.32, p<0.001 (p=0.0009). In IC patients, 1 (4.76%) had fibrosis and 20 (95.24%)) did not have fibrosis. Out of 23 patients with HBeAg negative chronic hepatitis B, 8 (34.78%) had fibrosis and 15 (65.22%) did not have fibrosis. Patients with HBeAg negative hepatitis B had significantly higher liver fibrosis than IC; Fisher Exact Test p<0.05 (p=0.02). The increase of HBsQ for one single unit (IU/ml) does not have predictive value for fibrosis (Ext (B) =1.00), 95% C.I. for EXP (B): 1.00-1.00 / p>0.05. Conclusion: Quantitative hepatitis B surface antigen has intermediate weak statistically insignificant prediction for liver fibrosis R=0.25 (p<0.10).

show abstract

Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients?

Cited by 10 publications

References 12 publications

Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection

Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection

Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients

Clinical Significance of Quantitative HBs Antigen in the Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B

Contact Info

Product

Resources

About